Medical Manager

William A. Golembieski

**** ******** ***** *****, ***. 301 Kentwood, MI 49512

248-***-**** • ******************@*****.***

PROFESSIONAL SUMMARY

I am an energetic, motivated researcher with a love of science. Proven organizational and leadership qualities looking for new challenges and opportunity for growth. Over 20 years of cancer research utilizing molecular biology techniques. Experienced in sterile cell culture methods.

EMPLOYMENT

Senior Research Coordinator

2013- 2015: Laboratory of Neuro-Oncology, Spectrum Health, Grand Rapids, MI.

Setup temporary lab to start basic research in Blodgett Hospital, East Grand Rapids.

Point person in planning and design of renovated research facility at Coopers Landing on Monroe Ave in Grand Rapids.

Investigation of signaling pathways when treating human glioma cells with P38 MAPK and Akt inhibitors, and with MK2 siRNA.

Senior Research Coordinator

1993 - 2013: Barbara Jane Levy Laboratory of Molecular Neuro-Oncology, Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, MI

Novel discovery that SPARC is upregulated in invasive Glioblastoma using a Subtractive Hybridization, thus changing the focus of the research in the Rempel lab for the last two decades.

Cloned SPARC into a tetracycline inducible vector, and then transfected a low expressing U87 cell line, increasing SPARC expression levels and altering the subsequent tumor phenotype in xenografts into one of high invasiveness.

Cloned SPARC into a GFP expression vector to study SPARC interactions using Fluorescent Microscopy, Imaging.

DNA and RNA isolation, Southerns, Northerns, cDNA Arrays, Cloning, Subcloning, Transformations. Subtractive Hybridizations, Differential Display.

Transfections, both transient and stable, and Lentiviral transfections.

Protein Isolations, Western Detections.

Trained and supervised medical fellows, Neurosurgery Residents, graduate students, summer students.

Played an integral role in the Rempel lab for three RO1 grants from the NIH, as well as various internal grants at Henry Ford Hospital.

Research Assistant/Lab Manager

1986- 1993: Department of Molecular Biology and Genetics, Wayne State University,

Detroit, MI

Cloning and mapping human genes on chromosome 3 using somatic cell hybrids.

DNA isolations, both plasmid and genomic.

Agarose gel electrophoresis, Restriction enzyme digestions, Sothern transfers, Southern hybridizations, Random primer labeling, pulsed field gel electrophoresis.

Trained and supervised summer students, medical students, undergraduate students, and Residents.

Directly involved in the research leading to the lab of Dr. David I. Smith obtaining RO1 funding from the NIH.

EDUCATION

Bachelor of Science, Microbiology University of Michigan

PUBLICATIONS

Thomas SL, Schultz CR, Mouzon E, Golembieski WA, Naili RE, Radakrishnan A, Lemke N, Poisson LM, Gutierrez JA, Cottingham S, Rempel SA. Loss of Sparc in p54-null Astrocytes Promotes Macrophage Activation and Phagocytosis Resulting in Decreased Tumor Size and Tumor Cell Survival. Brain Pathol. 2014 May 26. Doi:1111/bpa.12161. [Epub ahead of print].

Alam R, Schultz CR, Golembieski W, and Rempel SA. PTEN Suppression of SPARC-Induced Migration of Glioma Cells Correlates with the Suppression of pP38 MAPK and pMAPKAPK2 and the Differential Regulation of HSP27 Phosphorylation and Expression. Neuro Oncol. 15(4): p. 451-461, 2013. PMID: 2338228

Schultz CR, Golembieski WA, King DA, Brown SL, Brodie C, Rempel SA. Inhibition of HSP27 alone, or in combination with pAKT inhibition, as therapeutic approaches to target SPARC-induced glioma survival. Molecular Cancer 11:20, 2012.

McClung HM, Golembieski W, Schultz CR, Rempel SA. Deletion of the SPARC Acidic Domain or EGF-like Module Reduces SPARC-induced Migration and Signaling Through p38 MAPK/HSP27 in Glioma. Carcinogenesis 33:275-84, 2012.

Golembieski W, Thomas SL, Schultz CR, Yunker CK, McClung H, Cazacu S, Barker T, Sage EH, Brodie C, Rempel SA. HSP27 mediates SPARC-induced changes in glioma morphology, migration and invasion. Glia 56:1061-1075, 2008.

Yunker CK, Golembieski W, Lemke N, Cazacu S, Schultz CR, Brodie C, Rempel SA. SPARC-induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion. Int J Cancer 122:2735-2743, 2008.

Rempel SA, Hawley RC, Gutiérrez, JA, Mouzon E, Bobbitt KR, Lemke N, Schultz C, Schultz LR, Golembieski W, Koblinski J, VanOsdol S, Miller CG. Splenic and immune alterations of the Sparc-null mouse accompany a lack of immune response. Genes and Immunity 8:262-74, 2007.

Golembieski WA, Rempel SA. cDNA array analysis of SPARC-modulated changes in glioma gene expression. J Neurooncol 60(3):213-26, 2002.

Schultz C, Lemke N, Ge S, Golembieski WA, Rempel SA. Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res 62(21):6270-7, 2002.

Rempel SA, Golembieski WA, Fisher JL, Maile M, Nakeff A. SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. J Neurooncol 53(2):149-60, 2001.

Golembieski WA, Ge S, Nelson K, Mikkelsen T, Rempel SA. Increased SPARC expression promotes U87 glioblastoma invasion in vitro. Int J Dev Neurosci 17(5-6):463-72, 1999.

Rempel SA, Golembieski WA, Ge S, Lemke N, Elisevich K, Mikkelsen T, Gutiérrez JA. SPARC: A signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. J Neuropathol Exp Neurol 57(12):1112-21, 1998.

Rempel SA, Rosenblum ML, Mikkelsen T, Yan PS, Ellis KD, Golembieski WA, Sameni M, Rozhin J, Ziegler G, Sloane BF. Cathepsin B expression and localization in glioma progression and invasion. Cancer Res 54(23):6027-31, 1994.

Shridhar V, Golembieski W, Kamat A, Smith SE, Phillips N, Miller OJ, Miller Y, Smith DI. Isolation of two contigs of overlapping cosmids derived from human chromosomal band 3p21.1 and identification of 5 new 3p21.1 genes. Somat Cell Mol Genet 20(4):255-65, 1994.

Siden TS, Golembieski W, Kumlien J, Rohme D, Smith DI. Physical map of small cell lung cancer deletion region on short arm of human chromosome 3 (3p13-22) based on radiation fusion hybrid analysis. Somat Cell Mol Genet 20(2):121-32, 1994.

Secore SL, Walker AP, Herbstreith MH, Siddique T, Jeffers AJ, Deshields TR, Speer MC, Pericakvance MA, Golembieski WA, Smith DI, Hung WY, Yamaoka LH, Roses AD, Bartlett RJ. A StuI polymorphism on chromosome 3p14.1-14.2 (D3S622) defined by two polymorphic StuI sites 2.4 Kb apart. Nucl Acids Res 19:6439; 1991.

Smith DI, Liu W, Ginzinger D, Green P, Smith S, Wang N-D, Recchia F, Carolyn K, Drabkin HA. Golembieski WA. Localization of 616 human chromosome 3-specific cosmids using a somatic cell hybrid deletion mapping panel. Genomics 11:179-187; 1991.

Golembieski WA, Smith SE, Recchia FF, Judge A, Shridhar V, Miller OJ, Drabkin HA, Smith DI. Isolation of large numbers of chromosome 3-specific cosmids containing clusters of rare restriction sites. Am J Hum Genet 49:581-589; 1991.

Gemmill RM, Garcia M, Smith DI, Erickson P, Golembieski WA, Miller YE, Coyle-Morris J Tommerup N DrabkinHA. A 2.5 Mb physical map within 3p21.1 spans the breakpoint associated with Greig Cephalopolysyndactyly Syndrome. Genomics 11:93-102, 1991.

Hsieh WT, Fong D, Slone BF, Golembieski WA, Smith DI. Mapping of the gene for human cysteine proteinase inhibitor Stefin A, STF1, to human chromosome 3cen-q21. Genomics 9:207-209; 1991.

Smith DI, Golembieski WA, Drabkin H, Kiousis S. Identification of two cosmids derived from within chromosomal band 3 p21.1 that contain clusters of rare restriction sites and evolutionarily conserved sequences. Am J Hum Genet 45:443-447; 1989.

Smith DI, Mangrulker R, Geist R, Gilbert J, Kinsman K, Drabkin H, Golembieski WA. Saturation of human chromosome 3 with unique sequence hybridization probes. Genomics 4:453-459; 1989.

Smith DI, Golembieski WA, Gilbert J, Kizyma L, Miller OJ. Overabundance of rare cutting restriction endonuclease sites in the human genome. Nucl Acids Res 15:1173-1184; 1987.

Contact this candidate